Anteris Technologies Global Corp. (AVR) 株式分析

企業概要

Anteris Technologies Global Corp. is a structural heart company dedicated to the development and commercialization of minimally invasive medical devices designed to treat heart valve diseases. The enterprise operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, where innovation in device technology is critical for addressing severe aortic stenosis. The company employs a workforce of 174 individuals and holds a market capitalization of $535.75M, while reporting annual revenue of $1.91M based on trailing twelve-month data. These financial figures indicate a micro-cap status characterized by a significant disparity between the company's market valuation and its current revenue generation, suggesting a market premium driven by potential future product adoption rather than established sales volume.

財務健全性

The company reports revenue of $1.91M for the trailing twelve months, yet it simultaneously records a net income of $-94,144,000 and an EBITDA of $-92,233,000, revealing a cost structure where operating expenses vastly exceed revenue generation. This substantial gap between positive revenue and deeply negative net income implies that the company is burning cash rapidly to fund its research, development, and commercialization efforts without yet achieving profitability. Free cash flow stands at $-44,253,376, indicating that the company's financial flexibility is currently constrained by significant cash outflows required to sustain operations and growth initiatives. Profitability metrics further illustrate this challenge, with a gross margin of 70.3%, an operating margin of -9343.5%, and a profit margin of 0.0%, highlighting that while the cost of goods sold is low relative to sales, overhead and R&D costs are severely impacting overall operational efficiency. On the balance sheet, the company holds $12.08M in cash against $2.28M in debt, while the debt-to-equity ratio is listed as N/A due to the negative equity position. Despite the high leverage implied by negative equity, the current ratio of 0.73 suggests that current assets may be slightly insufficient to cover current liabilities without relying on external financing or asset liquidation. Return on Equity is recorded at -301.9% and Return on Assets at -113.2%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or deployed in assets.

バリュエーション評価

Valuation metrics for Anteris Technologies Global Corp. present an unusual picture given the lack of positive earnings, with a trailing P/E ratio of N/A and a forward P/E of -5.68. The absence of a trailing P/E reflects the company's unprofitable status over the last twelve months, while the negative forward P/E suggests that analysts or the market is pricing in a potential recovery in earnings, though the negative figure itself typically indicates that expected future earnings are also negative or the model relies on non-earnings-based valuation. The price-to-book ratio is an extreme -2755.00, which indicates that the market price per share is not supported by tangible book value in the traditional sense, often seen in biotech or device companies where intangible assets like intellectual property dominate the valuation. Alternative valuation metrics such as the price-to-sales ratio of 280.06 and an EV/EBITDA of -5.70 suggest that the market is assigning a very high multiple to the company's sales, implying that the stock price is driven heavily by growth expectations rather than current financial performance. The stock has traded between a 52-week high of $6.95 and a 52-week low of $2.34, and without a specific current price provided in the facts, the valuation context remains anchored to this wide trading range which reflects significant price volatility. The beta of 0.55 indicates that the stock price exhibits lower volatility relative to the broader market, moving with less intensity than the overall market index despite its small market capitalization.

Growth & Income

Revenue growth year-over-year is reported at -42.2%, while earnings growth is N/A due to the lack of prior comparable positive earnings data. The negative revenue growth rate indicates a contraction in sales or a decline in the performance of the DurAVR transcatheter heart valve system during the most recent period, which is a critical concern for a company relying on device sales for income. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders; instead, the company reinvests its limited cash flow into operational continuity and product development. The overall growth and income profile is defined by declining revenue and an absence of dividend income, relying entirely on the potential for future product approvals or sales expansion to alter its financial trajectory.